MetaCap

Biohaven (BHVN) vs Zymeworks (ZYME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biohaven (BHVN) has outperformed Zymeworks (ZYME) over the past year, gaining 27.9% versus a gain of 8.8%. Biohaven is the larger company by market cap ($1.87 billion vs $1.81 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BHVN+27.86%ZYME+8.83%
+79%+29%-21%
Nov 21, 20251 yearNov 20, 2026
BHVN+73.63%ZYME+396.02%
+749%+349%-50%
Sep 19, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BHVN versus ZYME key metrics
MetricBHVNZYME
Share price$12.39$26.14
Market cap$1.87B$1.81B
1-day change-9.23%-2.68%
YTD return+9.74%-0.72%
1-year return+27.86%+8.83%
5-year return—+34.05%
P/E ratio (TTM)—49.32
Forward P/E—54.95
EPS (TTM)$-3.77$0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$105.97M
Revenue growth (YoY)—+38.87%
Net income (latest FY)$-738.82M$-81.13M
Operating margin—-87.34%
Net margin—-76.56%
52-week high$18.24$31.97
52-week low$8.03$21.52
Distance from 52-week high-32.07%-18.24%
Analyst consensusbuystrong_buy
Avg. price target upside+102.82%+65.61%
Average volume3.24M1.09M
Shares outstanding151.06M68.70M
Employees274279
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BHVN has outperformed ZYME by 19.0 percentage points over the past year.

About Biohaven

BHVN stock →

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees

About Zymeworks

ZYME stock →

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees

BHVN vs ZYME FAQ

Which is bigger, Biohaven or Zymeworks?

Biohaven (BHVN) is larger, with a market capitalization of $1.87B compared with $1.81B for Zymeworks (ZYME).

Which stock has performed better over the past year, BHVN or ZYME?

BHVN returned +27.86% over the past 12 months, compared with +8.83% for ZYME (price return, excluding dividends). Past performance does not predict future results.

Are Biohaven and Zymeworks in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons